Clinical Trials Logo
  1. Home
  2. Clear Cell Sarcoma
  3. NCT03132155

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

Clear Cell Sarcoma Clinical Trial

Official title:
A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion

Clinical Trial Summary

This is a phase 2 study that will assess the efficacy of AMG 337 in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion.

Clinical Trial Description

The phase 2 single arm study will assess efficacy of AMG 337 (based on confirmed ORR) in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion, as determined by fluorescent in situ hybridization (FISH) or other diagnostic methods and confirmed by RNA sequencing (RNAseq). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03132155
Study type Interventional
Source NantPharma, LLC
Contact
Status Terminated
Phase Phase 2
Start date May 2, 2018
Completion date September 21, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03600649 - Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Phase 1
Recruiting NCT03618381 - EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Active, not recruiting NCT03989596 - Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Phase 2
Completed NCT02162732 - Molecular-Guided Therapy for Childhood Cancer N/A
Recruiting NCT04897321 - B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Phase 1
Active, not recruiting NCT04483778 - B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Enrolling by invitation NCT05266196 - A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Phase 1/Phase 2
Completed NCT02390843 - Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Phase 1
Recruiting NCT03967834 - Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group N/A
Completed NCT01331135 - Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Phase 1